By Fineline Cube 
China’s National Medical Products Administration (NMPA) has granted approval for 99mTc-3PRGD2, a Category 1 radionuclide drug conjugate (RDC) developed by Radio Medicinal, marking the world’s first broad-spectrum tumor imaging agent for SPECT imaging diagnosis.
Regulatory Approval Details
| Attribute | Detail |
|---|---|
| Drug Name | 99mTc-3PRGD2 |
| Classification | Category 1 RDC (innovative) |
| Developer | Radio Medicinal |
| Parent Company | Baheal Pharmaceutical Group (SHE: 301015) |
| Approval Authority | NMPA |
| Primary Indication | Auxiliary examination for regional lymph node metastasis in suspected lung cancer patients |
Technology & Mechanism of Action
Molecular Targeting
- Target Receptor: Integrin αvβ3
- Molecular Probe: RGD peptide-based
- Binding Specificity: Specifically binds to integrin αvβ3 receptors on:
- Tumor cells
- Tumor neovascular endothelial cells
Imaging Capabilities
- Modality: SPECT (Single Photon Emission Computed Tomography)
- Precision: Enables precise tumor imaging through targeted molecular binding
- Spectrum: Broad-spectrum applicability across multiple tumor types expressing integrin αvβ3
Development & Corporate Background
Radio Medicinal Profile
- Specialization: Nuclear medicine innovation enterprise
- Investment Structure: Incubated and invested by Baheal Pharmaceutical Group
- Strategic Focus: Development of novel radiopharmaceuticals and molecular imaging agents
Baheal Pharmaceutical Group
- Stock Exchange: Shenzhen Stock Exchange (SHE: 301015)
- Investment Strategy: Strategic incubation of specialized biotech companies in nuclear medicine
- Portfolio Expansion: Entry into diagnostic radiopharmaceuticals complements existing therapeutic portfolio
Clinical & Market Implications
Diagnostic Advancement
- Unmet Need Addressed: Improved detection of lymph node metastasis in lung cancer suspects
- Clinical Utility: Provides physicians with precise imaging tool for staging and treatment planning
- Broad Applicability: Potential expansion to other integrin αvβ3-expressing tumors beyond lung cancer
Market Positioning
- First-Mover Status: World’s first broad-spectrum tumor imaging agent creates significant competitive advantage
- Category 1 Designation: Highest innovation classification in China supports premium pricing and market exclusivity
- Nuclear Medicine Growth: Aligns with global trend toward precision molecular diagnostics in oncology
Strategic Significance
- China Innovation: Demonstrates China’s growing capability in advanced radiopharmaceutical development
- Diagnostic-Therapeutic Integration: Potential for theranostic applications combining diagnosis and targeted therapy
- Global Potential: First-in-world status positions product for international regulatory submissions
Forward‑Looking Statements
This brief contains forward-looking statements regarding market opportunities, clinical applications, and regulatory pathways. Actual commercial performance may vary based on market adoption, reimbursement policies, and competitive dynamics.-Fineline Info & Tech